PAH and phenylketonuria: A promising alternative for addressing PKU is mRNA replacement therapy.54 The Chivukula group55 introduced LNP-encapsulated full-length mRNA encoding human codon-optimized PAH (hPAH) in their proprietary lipid nanoparticle (lipid-enabled and unlocked nucleic acid modified RNA, LUNAR) designed to target hepatocytes.